Exact Sciences, the NSABP Foundation, and the German Breast Group Present Results for the Oncodetect® MRD Test in Early Triple-Negative Breast Cancer at SABCS

Core Insights - Exact Sciences Corp. announced the first clinical study results from its Oncodetect® molecular residual disease (MRD) test in breast cancer, indicating strong predictive capabilities for distant recurrence after surgery in early-stage patients [1] Group 1: Clinical Study Results - The NSABP B-59 substudy was conducted in collaboration with the NSABP Foundation and the German Breast Group (GBG) [1] - Findings demonstrate that the Oncodetect test is effective in predicting distant recurrence in patients with early breast cancer [1]